Logo image of ALCJ.PA

CROSSJECT (ALCJ.PA) Stock Fundamental Analysis

EPA:ALCJ - Euronext Paris - Matif - FR0011716265 - Common Stock - Currency: EUR

1.67  +0.06 (+3.99%)

Fundamental Rating

2

Overall ALCJ gets a fundamental rating of 2 out of 10. We evaluated ALCJ against 55 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of ALCJ have multiple concerns. ALCJ has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ALCJ has reported negative net income.
ALCJ had a negative operating cash flow in the past year.
In the past 5 years ALCJ always reported negative net income.
ALCJ had a negative operating cash flow in each of the past 5 years.
ALCJ.PA Yearly Net Income VS EBIT VS OCF VS FCFALCJ.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

ALCJ has a Return On Assets of -40.53%. This is amonst the worse of the industry: ALCJ underperforms 81.82% of its industry peers.
ALCJ's Return On Equity of -470.75% is on the low side compared to the rest of the industry. ALCJ is outperformed by 85.45% of its industry peers.
Industry RankSector Rank
ROA -40.53%
ROE -470.75%
ROIC N/A
ROA(3y)-34.88%
ROA(5y)-33.65%
ROE(3y)-354.28%
ROE(5y)-361.76%
ROIC(3y)N/A
ROIC(5y)N/A
ALCJ.PA Yearly ROA, ROE, ROICALCJ.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

ALCJ does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALCJ.PA Yearly Profit, Operating, Gross MarginsALCJ.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

1

2. Health

2.1 Basic Checks

ALCJ does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALCJ has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ALCJ has been increased compared to 5 years ago.
ALCJ has a worse debt/assets ratio than last year.
ALCJ.PA Yearly Shares OutstandingALCJ.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
ALCJ.PA Yearly Total Debt VS Total AssetsALCJ.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -0.10, we must say that ALCJ is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.10, ALCJ is doing worse than 76.36% of the companies in the same industry.
ALCJ has a Debt/Equity ratio of 6.53. This is a high value indicating a heavy dependency on external financing.
ALCJ's Debt to Equity ratio of 6.53 is on the low side compared to the rest of the industry. ALCJ is outperformed by 87.27% of its industry peers.
Industry RankSector Rank
Debt/Equity 6.53
Debt/FCF N/A
Altman-Z -0.1
ROIC/WACCN/A
WACC7.2%
ALCJ.PA Yearly LT Debt VS Equity VS FCFALCJ.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

A Current Ratio of 1.66 indicates that ALCJ should not have too much problems paying its short term obligations.
ALCJ has a Current ratio (1.66) which is in line with its industry peers.
ALCJ has a Quick Ratio of 1.08. This is a normal value and indicates that ALCJ is financially healthy and should not expect problems in meeting its short term obligations.
ALCJ has a Quick ratio (1.08) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 1.66
Quick Ratio 1.08
ALCJ.PA Yearly Current Assets VS Current LiabilitesALCJ.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for ALCJ have decreased strongly by -23.99% in the last year.
ALCJ shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)-23.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20.65%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

ALCJ is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 64.52% yearly.
ALCJ is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 98.55% yearly.
EPS Next Y163.92%
EPS Next 2Y104.3%
EPS Next 3Y64.52%
EPS Next 5YN/A
Revenue Next Year308.97%
Revenue Next 2Y140.35%
Revenue Next 3Y98.55%
Revenue Next 5YN/A

3.3 Evolution

ALCJ.PA Yearly Revenue VS EstimatesALCJ.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M
ALCJ.PA Yearly EPS VS EstimatesALCJ.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.5 -0.5

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALCJ. In the last year negative earnings were reported.
ALCJ is valuated reasonably with a Price/Forward Earnings ratio of 9.90.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ALCJ indicates a rather cheap valuation: ALCJ is cheaper than 94.55% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 37.36, ALCJ is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 9.9
ALCJ.PA Price Earnings VS Forward Price EarningsALCJ.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALCJ.PA Per share dataALCJ.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 -0.2

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ALCJ's earnings are expected to grow with 64.52% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y104.3%
EPS Next 3Y64.52%

More info and screens

0

5. Dividend

5.1 Amount

ALCJ does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CROSSJECT

EPA:ALCJ (7/23/2025, 7:00:00 PM)

1.67

+0.06 (+3.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-31 2025-03-31/amc
Earnings (Next)09-22 2025-09-22
Inst Owners0.56%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap84.72M
Analysts84.44
Price Target3.37 (101.8%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-14.29%
PT rev (3m)-14.29%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.8%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 9.9
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 31.17
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.28
EYN/A
EPS(NY)0.17
Fwd EY10.1%
FCF(TTM)-0.23
FCFYN/A
OCF(TTM)-0.16
OCFYN/A
SpS0
BVpS0.05
TBVpS-0.14
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -40.53%
ROE -470.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-34.88%
ROA(5y)-33.65%
ROE(3y)-354.28%
ROE(5y)-361.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 6.53
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 67.57%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.66
Quick Ratio 1.08
Altman-Z -0.1
F-Score3
WACC7.2%
ROIC/WACCN/A
Cap/Depr(3y)131.18%
Cap/Depr(5y)130.12%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-23.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20.65%
EPS Next Y163.92%
EPS Next 2Y104.3%
EPS Next 3Y64.52%
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year308.97%
Revenue Next 2Y140.35%
Revenue Next 3Y98.55%
Revenue Next 5YN/A
EBIT growth 1Y-9.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year289.89%
EBIT Next 3Y71.59%
EBIT Next 5YN/A
FCF growth 1Y8.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-28.35%
OCF growth 3YN/A
OCF growth 5YN/A